EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Cognitive function during endocrine treatment with or without cyclin‐dependent kinase 4/6 inhibitors for advanced breast cancer

Maryse J Luijendijk iD, Philippe R Lee Meeuw Kjoe, Noor Wortelboer iD, Annemiek van Ommen-Nijhof, A Elise van Leeuwen-Stok, Joost A Agelink van Rentergem, Ivar E Vermeulen, Inge R Konings, Agnes Jager, Gabe S Sonke, Elsken van der Wall, Sanne B Schagen

Cancer · 15.12.2025 · 131 (24)

DOI: 10.1002/cncr.70212 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer, online erschienen am 10.12.2025. Verfasst von Maryse J Luijendijk und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Cognition. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: KWF Kankerbestrijding, ZonMw, Zorgverzekeraars Nederland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Endocrine treatment for breast cancer may adversely affect cognition. Given the widespread use of cyclin‐dependent kinase 4/6 inhibitors (CDK4/6i), assessing the cognitive effects of this combination is important.

Methods

In the SONIA trial, patients with hormone receptor–positive, HER2‐negative (HR + HER2 − ) advanced breast cancer (ABC) starting first‐line treatment with an aromatase inhibitor were randomized to treatment with (arm A) or without (arm B) CDK4/6i. Cognitive function was assessed at baseline and after 9 months with the online Amsterdam Cognition Scan. Standardized z scores at baseline and regression‐based change scores at 9 months were computed on the basis of matched cancer‐free controls. Rates of clinically meaningful decline were compared with estimated false‐positive rates of observing decline by chance.

Results

Altogether, 260 patients (arm A, N = 130; arm B, N = 130) and 130 matched controls participated at baseline; 199 patients (arm A, N = 108; arm B, N = 91) and 120 matched controls completed the follow‐up. At baseline, patients performed significantly worse than controls across all cognitive domains. Over the course of 9 months, no group‐level decline in cognitive function occurred in either treatment arm, with minimal differences between treatment arms. At the individual level, however, the rate of clinically meaningful decline in patients (arm A, 15.7%; arm B, 14.3%) but not in controls (6.7%) was significantly higher than the false‐positive rate (7.5%), which indicates decline in a small subset of patients.

Conclusions

Patients with HR + HER2 − ABC showed impaired cognitive function at initial diagnosis compared to cancer‐free controls. During first‐line endocrine treatment with aromatase inhibitors, cognitive function declined in a small group of patients, regardless of the addition of CDK4/6i.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6CognitionAromatase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsProtein Kinase InhibitorsHumansFemaleMiddle AgedAgedAdultErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

cancer‐related cognitive impairmentcognitive dysfunctionendocrine treatmentmetastatictargeted therapy

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Aromatase InhibitorsProtein Kinase InhibitorsErb-b2 Receptor Tyrosine KinasesCDK6 protein, humanCDK4 protein, human

Autor:innen und Institutionen

  • Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Dutch Breast Cancer Research Group (BOOG), BOOG Study Center, Utrecht, The Netherlands.
  • Department of Communication Science, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands.

ORCID-Profile: Maryse J Luijendijk, Noor Wortelboer

Förderung

  • KWF Kankerbestrijding
  • ZonMw
  • Zorgverzekeraars Nederland

Zitieren

APA

Luijendijk, M. J., Lee Meeuw Kjoe, P. R., Wortelboer, N., van Ommen-Nijhof, A., van Leeuwen-Stok, A. E., Agelink van Rentergem, J. A., Vermeulen, I. E., Konings, I. R., Jager, A., Sonke, G. S., van der Wall, E., & Schagen, S. B. (2025). Cognitive function during endocrine treatment with or without cyclin‐dependent kinase 4/6 inhibitors for advanced breast cancer. Cancer, 131(24). https://doi.org/10.1002/cncr.70212

Vancouver

Luijendijk MJ, Lee Meeuw Kjoe PR, Wortelboer N, van Ommen-Nijhof A, van Leeuwen-Stok AE, Agelink van Rentergem JA, et al. Cognitive function during endocrine treatment with or without cyclin‐dependent kinase 4/6 inhibitors for advanced breast cancer. Cancer. 2025;131(24). doi:10.1002/cncr.70212

BibTeX
@article{Luijendijk2025,
  author = {Luijendijk, Maryse J and Lee Meeuw Kjoe, Philippe R and Wortelboer, Noor and van Ommen-Nijhof, Annemiek and van Leeuwen-Stok, A Elise and Agelink van Rentergem, Joost A and Vermeulen, Ivar E and Konings, Inge R and Jager, Agnes and Sonke, Gabe S and van der Wall, Elsken and Schagen, Sanne B},
  title = {Cognitive function during endocrine treatment with or without cyclin‐dependent kinase 4/6 inhibitors for advanced breast cancer},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {24},
  doi = {10.1002/cncr.70212}
}
Kostenlos starten →